Morepen Laboratories Completes First Expansion Phase, Reaching 614 KL Capacity

Morepen completed the first phase of its manufacturing expansion ahead of schedule, increasing API and CDMO reactor capacity from 535 KL to 614 KL. The added capacity supports ongoing commercial CDMO scale-up, existing API operations and future customer programs.